Product
LYB002V14
Aliases
30μg dose of LYB002V14, 60μg dose of LYB002V14
2 clinical trials
2 indications
Indication
COVID-19Indication
COVID-19 vaccineClinical trial
A Randomized, Blinded, Placebo-Controlled, Dose Escalation Phase 1 Trial of Recombinant COVID-19 Trivalent (XBB.1+BQ.1.1+Prototype) Protein Vaccine (CHO Cell)(LYB002V14) in Booster Vaccination in Participants Aged 18 Years Old and AboveStatus: Not yet recruiting, Estimated PCD: 2024-12-26
Clinical trial
To Evaluate the Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Trivalent Vaccine (CHO Cell) LYB002 in Chinese Adults 18 Years and Above Completed Three-dose Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2023-07-31